Final results from the randomized trial of Sutent in pancreatic neuroendocrine tumors was released in Orlando today, and they are good enough to send Pfizer to the FDA seeking an approval. Evidently Sutent extended overall (a secondary endpoint) and progression-free survival in the studies, according to researchers.

This was in a pretreated population of patients. Sutent was compared to placebo, so the setting appears to be people with advanced disease.

Long-acting Sandostatin delays progression of neuroendocrine tumors. Steve Jobs may want to take notice of a result presented at the 2009 Gastrointestinal Cancers Symposium: Sandostatin LAR delays progression of metastatic neuroendocrine tumors. These smaller tumor-focused meetings such as San Antonio for breast cancer and now the annual GI Cancers Symposium frequently present higher quality data than the larger ASCO annual meeting. Cancer information is getting even more fragmented though the pace of discovery is about the same as it's been in the past.